Sign Out
Hypersensitivity to tranexamic acid or any component of the product.
Active thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, cerebral thrombosis).
History of thrombosis or thromboembolism (e.g., retinal vein or artery occlusion) or intrinsic risk of thrombosis or thromboembolism (e.g., thrombogenic valvular disease, thrombogenic cardiac rhythm disease, hypercoagulopathy), unless at the same time it is possible to give treatments with anticoagulants.
Patients receiving thrombin because of increased risk of thrombosis.
Patients with acquired disturbances of color vision. If disturbances of color vision arise during the course of treatment, discontinue the drug.
Patients with subarachnoid hemorrhage since cerebral edema and cerebral infarction may be caused by tranexamic acid in such cases.
Continue with Google